Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
lintuzumab · 3 trials · 5 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Lintuzumab plus low dose cytarabine |
| 2 | ACTIVE_COMPARATOR | Placebo plus low dose cytarabine |
| Name | Type | Description |
|---|---|---|
| Lintuzumab (SGN-33) | DRUG | 600 mg IV on days 1, 8, 15 and 22 of cycle 1 and days 1 and 15 of each subsequent 28-day cycle up to a maximum of 12 cycles. |
| Low dose cytarabine | DRUG | 20 mg SC twice a day on days 1-10 of each 28 day cycle up to a maximum of 12 cycles. |
| Placebo | DRUG | IV administration on days 1, 8, 15, and 22 of cycle 1 and days 1 and 15 of each subsequent 28-day cycle up to a maximum of 12 cycles |
| lintuzumab | DRUG | 4 or 8 mg/kg IV (in the vein) on Days 1, 8 and 15 for the first 21-day cycle; 4 or 8 mg/kg IV (in the vein) on Days 1 and 8 for the second through the eighth 21-day cycle |
| lenalidomide | DRUG | 10 or 15 mg per day, taken orally on Days 1-14 of each 21-day cycle |
Inclusion Criteria: * Untreated AML that occurred de novo, after prior exposure to chemotherapy for a separate malignancy, or evolved from an antecedent hematologic disorder. * After being informed of the potential benefits and risks of available treatment options, patients must have declined inten...
Lintuzumab is an investigational drug being studied for the treatment of Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). It is in Phase 2 clinical development for these oncology indications. Lintuzumab is not approved by the FDA and remains under investigation.
Lintuzumab is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 2 clinical development for the treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Lintuzumab is in Phase 2 clinical development. It has completed two Phase 1 trials and one Phase 2 trial. The drug is investigational and has not been approved by the FDA for any indication.
Lintuzumab has been studied in three completed clinical trials. NCT00283114 was a Phase 1 safety study in patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. NCT00502112 was a Phase 1 study combining lintuzumab with lenalidomide in MDS patients. NCT00528333 was a Phase 2 study combining lintuzumab with low dose cytarabine in AML patients aged 60 and older.
Yes, lintuzumab is also known as SGN-33. In clinical trial NCT00528333, the drug is referred to as lintuzumab (SGN-33). This alternative name may appear in older literature or trial records.